Galapagos NV announced its first quarter financial results and recent business highlights, including the dosing of the first U.S. patient in the ATALANTA-1 study of GLPG5101 for mantle cell lymphoma. The company is advancing its cell therapy pipeline, with pivotal development for GLPG5101 planned for 2026 and aims for approval in 2028. Additionally, Galapagos is undergoing executive leadership changes and planning a separation into two entities, with SpinCo focusing on oncology, immunology, and virology. The company reported €3.3 billion in cash and reaffirmed its annual cash burn guidance.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.